today show semaglutide Weight loss drugs help change stigmas around obesity Hi everyone! 👋 There's still

If patients do not tolerate the 25 mg once daily maintenance dosage, consider switching to WEGOVY injection 1.7 mg once weekly [see Dosage and Administration (2.5)]

Fermentation of soluble fiber in the colon produces short-chain fatty acids (SCFAs)

The SELECT trial, published in The Lancet (October 22, 2025), provides a landmark analysis confirming that the cardioprotective benefits of semaglutide extend beyond weight loss alone. The SELECT Trial: Study Overview The SELECT trial (NCT03574597) enrolled 17,604 participants aged 45 years and above across 41 countries and 804 sites

Obesity reviews : an official journal of the International Association for the Study of Obesity, 17(10), 970976